Tumor Agnostic testing – Awareness of biomarkers, Market landscape and Approaches

Tumor agnostic indications present specific challenges that must be addressed to achieve a successful launch and ensure wide access for all patients.

To prepare for these complex product and indications launches, it is paramount for commercial teams to gain insights on tumor agnostic testing behaviors, including awareness, adoption, drivers and barriers.

Purdie Pascoe conducted a global research survey with medical oncologists to understand the current state of tumor agnostic testing, how physicians are approaching it, which upcoming biomarkers they are aware of, and what are the main drivers and barriers to tumor agnostic testing.

For more information, reach out to our Precision Medicine and Diagnostics team.